2 / 24
Page 38
Notes:
conferenceseries
.com
Volume 7, Issue 4 (Suppl)
Clin Exp Pharmacol
ISSN: 2161-1459 CPECR, an open access journal
Pharmacology Congress 2017
July 24-25, 2017
July 24-25, 2017 Melbourne, Australia
8
th
World Congress on
Pharmacology and Toxicology
An isoflavone compound Daidzein elicits myoblast differentiation and myotube growth
Gyu-Un Bae
Sookmyung Women’s University, Republic of Korea
T
he reduced regenerative capacity of muscle stem cells contributes to aging or disease-related skeletal muscle atrophy.
Daidzein, a natural isoflavone from Leguminosae, improves insulin sensitivity in skeletal muscle and prevents TNF-α
induced muscular atrophy. However, the molecular mechanisms by which daidzein exerts these beneficial effects are currently
unknown. In this study, we determined the effect and molecular mechanisms by which daidzein might improve skeletal muscle
function. Similarly to the results with TNF-α, daidzein treatment prevented myotube atrophy triggered by Dexamethasone
(DEX) via Akt activation. Furthermore, daidzein promoted myoblast differentiation in a dose-dependent manner through
activation of promyogenic kinases, Akt and p38MAPK. Daidzein treatment strengthened MyoD activation by enhancing its
heterodimer formation with E protein. Additionally, daidzein induced myotube growth, through activation of Akt/mTOR/S6K
pathway. Moreover, daidzein increased MyoD-dependent myogenic conversion of fibroblast and myogenic differentiation.
Taken together, daidzein has a potential as a therapeutic or nutraceutical remedy to improve muscle function and to treat aging
or disease-related muscle loss and weakness.
Biography
Gyu-Un Bae has completed his PhD from Sungkyunkwan University and Postdoctoral studies from Harvard University, School of Medicine. He has published
more than 54 papers in reputed journals and has been serving as an Editorial Board Member of Archives of Pharmacal Research.
gbae@sm.ac.krGyu-Un Bae, Clin Exp Pharmacol 2017, 7:4 (Suppl)
DOI: 10.4172/2161-1459-C1-020